alexa Permanent Neonatal DM in Monozygotic Twins with p.C109Y Mutation in INS Gene: First Report from Saudi Arabia | OMICS International
ISSN: 2155-6156
Journal of Diabetes & Metabolism

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Permanent Neonatal DM in Monozygotic Twins with p.C109Y Mutation in INS Gene: First Report from Saudi Arabia

Iman M. Talaat1,2, Naglaa Mohamed Kamal3,4* and Hamid Alghamdi2

1Faculty of Medicine, Ain Shams University, Egypt

2Consultant Pediatrician, Prince Mansour Hospital, Taif, Saudi Arabia

3Faculty of Medicine, Cairo University, Cairo, Egypt

4Consultant Pediatrician, Al-Hada Armed Forces Hospital, Taif, Saudi Arabia

*Corresponding Author:
Naglaa Mohamed Kamal
Pediatrics, Associate Professor of Pediatrics, Faculty of Medicine
Cairo University, Cairo, Egypt
Tel: 00201141991114
E-mail: [email protected]

Received date: December 27, 2013; Accepted date: January 29, 2014; Published date: February 05, 2014

Citation: Talaat IM, Kamal NM, Alghamdi H (2014) Permanent Neonatal DM in Monozygotic Twins with p.C109Y Mutation in INS Gene: First Report from Saudi Arabia. J Diabetes Metab 5: 332. doi:10.4172/2155-6156.1000332

Copyright: © 2014 Talaat IM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Diabetes & Metabolism


Insulin gene mutation (INS) is the second most common cause of permanent neonatal diabetes (PNDM). We present the 1st cases of Saudi monozygotic twins with permanent neonatal diabetes mellitus who had simultaneous onset of disease due to p.C109Y (p.Cys109Tyr, c.326G>A) heterozygous missense mutation in exon 3 of the insulin (INS) gene. The twin patients had the same mutation while their parents are unaffected with normal genetic testing suggesting that this mutation had raised de novo. This p.C109Y mutation affects a highly conserved cysteine residue which is crucial for protein folding. Subjects with this form of diabetes will need lifelong insulin therapy.


Permanent neonatal Diabetes; Monozygotic; Twins; INS gene; Saudi Arabia


Neonatal diabetes mellitus (NDM) was previously defined as diabetes with onset within 6 weeks from birth that requires insulin therapy for at least 2 weeks. The new definition recently adopted, includes patients with diabetes onset within 6 months of age [1]. NDM was considered exceedingly rare condition but actually its incidence varies from country to another [1]. High incidence of 1 in 21,196 live births was reported from Saudi Arabia [2].

NDM can be classified according to the duration of insulin dependence in the first months/years of life and according to the molecular mechanisms responsible for the severe insulin secretion deficiency into 2 types; transient or permanent [3]. The number of cases of neonatal diabetes continues to accumulate, but the available, combined data indicate that somewhat over half (~57%) of NDM cases are transient [4].

Permanent neonatal diabetes mellitus (PNDM) /monogenic diabetes of infancy (MDI) is a rare condition associated with defects in genes that play major roles in pancreatic beta cell development and function; mutations in the genes encoding the ATP-sensitive potassium channel (K-ATP) subunits, KCNJ11 (encoding KIR 6.2 subunit), ABCC8 (encoding SUR1 subunit) and insulin (INS), account for most cases of PNDM/MDI [4-10]. Moreover, individuals with some exceedingly rare forms of syndromic PNDM may bear recessive mutations in several genes, including PDX1, EIF2AK3, PTFIA, GLIS3, RFX6 or FOXP3 [11-17] , while recessive mutations in glucokinase give rise to isolated neonatal diabetes [18].

In fact undoubtedly the discovery of INS mutations on chromosome 11p15 [8] was the most important discovery in PNDM from the clinical perspective in the last few years [8]. It accounts for about 10-15% of NDM cases [3,9,19,20]. Both heterozygous and homozygous INS mutations can cause NDM. The heterozygous coding mutations in the INS gene are considered the second most common cause of isolated PNDM after the activating mutations in the KATP channel genes [3,8,9,20]. Recently Raile et al. reported INS deletions in homozygous and heterozygous individuals [21].

Case Report

We here in report the first cases of PNDM due to INS heterozygous mutation from Saudi Arabia in 15 years-old identical twin females, born to non-consanguineous parents. They were delivered at term by normal spontaneous vertex vaginal delivery with uneventful antenatal and postnatal periods. Family history was negative for DM. At birth, their general condition was unremarkable with birth weight 2.3 kg (twin 1) and 2.1 kg (twin 2). At the age of 3 months, their mother noticed irritability and fussiness with failure to gain weight for both of her daughters simultaneously. Random blood glucose was checked and found to be 340 mg/dl (twin 1) and 500 mg/dl (twin 2) with no ketosis. Thyroid function tests and lipid profile were normal. Structural diseases of the pancreas were excluded by ultrasonography of the abdomen. They were started on NPH insulin with dose of about 1 unit/kg/day. Glutamic acid decarboxylase-65 antibody (GAD-65) and anti-islet cell antibodies were negative. Celiac profile was also negative. Basal and glucagon stimulated C-peptide levels were undetectable (reference range: 1.1-4.4 ng/mL). Since diagnosis, the patients are being followed up and they are now 15 years old with average weight and height and normal motor, mental and pubertal development with no extrapancreatic disease. They are currently on insulin glargine only with a dose of about 1 unit per kg and refusing the short acting analogues with poor glycemic control (HbA1C between 10-14%). As previously reported by Kamal Alanani and Alsulaimani, low awareness and persistent denial of the parents about the fact that their children are diabetic is the greatest obstacle Pediatricians meet in Saudi Arabia [22]. We faced that in our patients whose parents are very poorly compliant to give proper insulin regimens to their daughters. Their parents were interviewed many times by multi-disciplinary team approach including; the pediatric endocrinologist, dietitians, nutritionists, health educators, diabetic educators, social workers, and psychiatrists, but with poor outcome. The child neglect committee was also involved. Currently, our main concern is to convince the parents for insulin pump therapy with the fact that it will be provided free of charge to their twins!

Genetic testing was carried for the patients and their parents. Sequence analysis of coding and flanking intronic of the KCNJ11 gene (NM_000525.3), ABCC8 gene (U63421and L78208), EI2AK3 gene (AF110146.1) and INS gene (NM_000207.2) were done. Genetic tests for mutations in the gene subunits of the ATP-sensitive potassium channel, which are commonly associated with NDM, were negative. Both the twin sisters had a heterozygous missense mutation, (p.Cys109Tyr, c.326G>A) in exon 3 of the INS gene (Figure 1). This mutation results in the substitution of tyrosine for cysteine at codon 109. The mutation was not detected in the parental samples and it is therefore likely that the mutation has raised de novo (Figure 1) (Parents tested by Sanger sequencing). The twins tested using a set of microsatellite markers (powerplex 16) and results are consistent with them being monozygous. Figure 2, illustrates the monozygosity of the twin patients.


Figure 1: Mutation Chromatography showing the mutation in both twins and the wild type in the parents.


Figure 2: Diagram showing the monozygozisity of the twin patients.


Neonatal diabetes mellitus due to insulin gene mutation constitutes around 10-15% of all PNDM in some reports [3,9,19,20], while in others it reached up to 20% as in the ISPAD cohort compared with 4% for ABCC8 and 35% for KCNJ11 mutations [3]. Compared to K-ATP channel mutations, cases with INS mutations have a later presentation of diabetes (our twins presented at the age of 3 months) [3]. Several studies using linkage and candidate gene-based approaches have reported heterozygous missense mutations in the insulin gene causing permanent neonatal diabetes mellitus [3,8,9,20,23]. In 2007 Stoy et al. reported 10 heterozygous mutations in the INS gene in 16 probands with PNDM namely; A24D, G32S, G32R, C43G, G47V, F48C, G90C, C96Y, Y108C and R89C [8]. Polak et al. 2008 reported also the A24D, R89C, and C96Y mutations [3]. In 2012, Catli et al. reported a novel p.L30Q mutation [24]. We hereby report second siblings and 1st twins with a new mutation p.C109Y in the INS gene after the one recently reported by Bee et al. [25].

This cysteine residue at codon 109 is highly conserved across species and the mutation abolishes a cysteine residue that is crucial for insulin folding [8] results in the formation of abnormally folded proinsulin molecules which are consequently degraded in the endoplasmic reticulum. This leads to severe endoplasmic reticulum stress followed by β cell death from apoptosis. Disulfide bonding seems to be crucial for proinsulin folding in the endoplasmic reticulum, and about 60% of the insulin gene mutations disrupt disulfide bridge formation within this protein either by substitution of a cysteine residue or by the creation of an additional cysteine [20].

Germ line mosaicism was reported involving either KCNJ11 mutation [26] or insulin gene [23,25]. Although we shared Bee et al. [25,26] same mutation but in their report the father had somatic mosaicism leading to transmission of PNDM to his children. Low level mutation was detected in the father’s sequencing trace. Real-time polymerase chain reaction analysis showed that he had approximately 73% of the mutant allele relative to his affected son. This was in contrary to our report where the parents’ genetic testing was completely normal. Age of onset in our reported patients (3 months) was comparable to that in the siblings reported by Bee et al. [25] (3 and 7 months).

Clinically, patients with an insulin gene mutation have severe hyperglycemia, and ketoacidosis [3,20,27], however, presentation is variable and, of these patients, only 40% had marked hyperglycemia and about 59% had ketoacidosis [20]. The presented patients had marked hyperglycemia and no previous history of diabetic ketoacidosis. Birth weight is variable may be low or high depending on the rate of reduction of β cell in utero or in the first year of life [8]. The birth weight of our twins was normal, which is consistent with the birth weight of most patients with insulin gene mutation in the study of Colombo et al. [9].

Since INS is mostly expressed in pancreatic β-cells, the affected patients do not show any extrapancreatic features which are consistent with our findings. In addition to causing NDM, INS mutations may present acutely after the first 6 months of age and even beyond the age of one year, when monogenic diabetes becomes exceedingly rare [28]. Furthermore, up to 70% of the mutations are de novo, so that family history of early-onset diabetes is lacking which is in accordance with our patients. It is therefore likely that some patients with an INS mutation are clinically indistinguishable from early-onset type-1-DM. In these cases, routine measurement of pancreatic autoantibodies in young children with diabetes may be a helpful tool to identify candidates for genetic testing [29]. In our patients, both GAD-65 and ICA antibodies were negative.

Based on the study carried by Habeb et al. [2] regarding the etiology of neonatal diabetes in KSA, where neither KCN11 nor ABCC8 nor INS mutation were detected, our twins are considered the first reported cases of PNDM with insulin gene mutation from Saudi Arabia.

A better understanding of the mechanism(s) leading to β-cell dysfunction in the patients with diabetes caused by an INS mutation will be crucial to define new treatments. As in the Akita mouse model, it may relate to the general concept of protein toxicity [30]. Strategies to increase insulin secretion by upregulating the normal allele of the INS gene may be applicable [3] and siRNA therapy for INS mutation is to be considered. Since INS mutations usually results in accumulation of a misfolded proinsulin molecule in the endoplasmic reticulum (ER), leading to ER stress and β-cell apoptosis[9], insulin is considered the only treatment currently available [31].

In summary, our case report highlighted the role of insulin gene mutation as a cause of neonatal diabetes in Saudi Arabia which was not noted as a common cause of neonatal diabetes before. To the best of our knowledge, this is the first reported case worldwide monozygotic twins presented with PNDM with INS gene mutation. The only reported monozygotic twins with PNDM are due to KCNJ11 mutation of the K-ATP channel [32].

We recommend that genetic testing for both the insulin gene as well as the channel mutations be carried out in all cases of neonatal diabetes and their parents, to identify the risk of recurrence in other siblings and meanwhile, this will help in premarital counseling in a community like Saudi Arabia with very high incidence of consanguineous marriage. It will also uncover cases which present late and misdiagnosed as type 1 DM in absence of positive autoantibodies.


“The molecular genetic testing was performed by Dr. Sarah Flanagan at the University of Exeter Medical School and funded by a Wellcome Trust Senior Investigator award to Professor Sian Ellard and Professor Andrew Hattersley”.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • International Conference on Internal Medicine May 21-22, 2018 Osaka, Japan
    May 21-22, 2018 Osaka, Japan
  • International conference on Fitness and Expo June 04-05, 2018 Baltimore, Maryland, USA
    June 4-5, 2018 Baltimore, USA
  • Annual Congress on Research and Innovations in Medicine July 02-03, 2018 Bangkok, Thailand
    July 02-03, 2018 Bangkok, Thailand
  • International Conference on Medical and Health Science August 24-25, 2018 Tokyo, JAPAN
    August 24-25, 2018 Tokyo, Japan

Article Usage

  • Total views: 12115
  • [From(publication date):
    February-2014 - May 22, 2018]
  • Breakdown by view type
  • HTML page views : 8336
  • PDF downloads : 3779

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7